Skip to main content

293 (UR N-C hyoscyamine 0.12 mg / methenamine 81.6 mg / methylene blue 10.8 mg / phenyl salicylate 36.2 mg / sodium phosphate monobasic 40.8 mg)

Generic Name: hyoscyamine/methenamine/methylene blue/phenyl salicylate/sodium biphosphate

Pill with imprint 293 is Purple, Round and has been identified as UR N-C hyoscyamine 0.12 mg / methenamine 81.6 mg / methylene blue 10.8 mg / phenyl salicylate 36.2 mg / sodium phosphate monobasic 40.8 mg. It is supplied by Libertas Pharma, Inc.

UR N-C is used in the treatment of urinary tract infection and belongs to the drug class urinary antispasmodics. Risk cannot be ruled out during pregnancy. UR N-C hyoscyamine 0.12 mg / methenamine 81.6 mg / methylene blue 10.8 mg / phenyl salicylate 36.2 mg / sodium phosphate monobasic 40.8 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for 293

Ur N-C hyoscyamine 0.12 mg / methenamine 81.6 mg / methylene blue 10.8 mg / phenyl salicylate 36.2 mg / sodium phosphate monobasic 40.8 mg 293

UR N-C

Generic Name
hyoscyamine/methenamine/methylene blue/phenyl salicylate/sodium biphosphate
Imprint
293
Strength
hyoscyamine 0.12 mg / methenamine 81.6 mg / methylene blue 10.8 mg / phenyl salicylate 36.2 mg / sodium phosphate monobasic 40.8 mg
Color
Purple
Shape
Round
Availability
Prescription only
Drug Class
Urinary antispasmodics
Pregnancy Category
C - Risk cannot be ruled out
CSA Schedule
Not a controlled drug
Labeler / Supplier
Libertas Pharma, Inc.
National Drug Code (NDC)
51862-0175 (Discontinued)
Inactive Ingredients
carbomer homopolymer type B, D&C Red No. 27, FD&C Blue No. 2, FD&C Red No. 40, magnesium stearate, microcrystalline cellulose, water, corn starch, magnesium silicate, titanium dioxide

Note: Inactive ingredients may vary.

Get help with Imprint Code FAQs.

Related images for "293"

More about UR N-C (hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium biphosphate)

Patient resources

Other brands

Uribel, Uro-MP, Uretron DS, Urelle, ... +15 more

Related treatment guides

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.